Amgen NASDAQ: AMGN pharmaceutical powerhouse just released a report stating positive performance results for Pivotal Postmenopausal Osteoporosis Trial for denosumab.

Trial met primary endpoint of Diminishing new vertebral fractures and secondary endpoints of decreasing time to first non-vertebral and hip fractures; adverse events similar to placebo. The immediate past president of the National Osteoporosis Foundation Stated, " I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."

Denosumab is the premier fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (these are the cells that break the bone down). Denosumab is being investigated for its ability to inhibit every stage of osteoclast activity through a targeted mechanism. Denosumab is being researched for a variety of bone loss illnesses including postmenopausal osteoporosis, rheumatoid arthritis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its ability to defer bone metastases and inhibit and treat bone destruction for many stages of cancer.

Osteoporosis is often referred to as the "silent epidemic", osteoporosis is a world wide problem illness that is increasing in significance as the population of the world both increases and ages. The World Health Organization (WHO) has recently claimed osteoporosis as a significant health issue along with other major non-communicable diseases. We are dependent on the pharmaceutical companies to help combat this horrendous disease.

According to Amgen the financial burden of osteoporosis is comparable to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).

Pharmacist-clinical have been developing prescriptions drugs to help patient that have serious side effects. These products are created almost at the same time as the medications that aid in the treatment of the initial illness. The fact that information is available to help anticipate the possible side effects and interactions drugs have with one another is awesome.

These medicines are used to both prevent and treat osteoporosis. Some medicines increase bone thickness or slow the rate of bone loss. Even small amounts of new bone growth can diminish the risk of broken bones. It is essential that you take vitamin D and calcium, eat well and exercise when you take osteoporosis prescriptions.